Sanofi (XSWX:SAN) Accounts Payable: CHF6,584 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:SAN Sanofi SA XSWX:SAN
91 GF Score
Price CHF73.20
GF Value CHF103.32
! 2 Warning Signs
View Full Analysis

What is Sanofi Accounts Payable?

Sanofi XSWX:SAN 91 Accounts Payable is CHF6,584 Mil as of Jun. 2026. GuruFocus rates XSWX:SAN with a GF Score™ of 91/100 and a GF Value™ of CHF103.32. The stock has 2 warning signs investors should review.

Sanofi's Accounts Payable for the quarter that ended in Jun. 2026 was CHF6,584 Mil.

Sanofi's quarterly Accounts Payable increased from Jun. 2025 (CHF6,636 Mil) to Dec. 2025 (CHF6,869 Mil) but then declined from Dec. 2025 (CHF6,869 Mil) to Jun. 2026 (CHF6,584 Mil).

Sanofi's annual Accounts Payable increased from Dec. 2023 (CHF6,911 Mil) to Dec. 2024 (CHF7,050 Mil) but then declined from Dec. 2024 (CHF7,050 Mil) to Dec. 2025 (CHF6,869 Mil).

Sanofi Accounts Payable Historical Data

* Premium members only.

The historical data trend for Sanofi's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Accounts Payable Chart

Sanofi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,431.39 6,723.51 6,910.86 7,049.71 6,868.83

Sanofi Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7,151.36 7,049.71 6,635.98 6,868.83 6,584.10
XSWX:SAN
91GF Score
Sanofi SA XSWX:SAN
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of CHF6,584 Mil mean?
Sanofi (XSWX:SAN) has a Accounts Payable of CHF6,584 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sanofi and its competitors.
Is Sanofi's Accounts Payable too high?
Sanofi's current Accounts Payable is CHF6,584 Mil. Overall, Sanofi has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi's Accounts Payable compare to LLY and JNJ?
Sanofi's Accounts Payable of CHF6,584 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Drug Manufacturers company?
A good Accounts Payable depends on the Drug Manufacturers industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Sanofi and its competitors. Sanofi's current Accounts Payable is CHF6,584 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi stock overvalued right now?
Sanofi (XSWX:SAN) has a current Accounts Payable of CHF6,584 Mil. The stock's GF Value™ is CHF103.32, compared to a current price of CHF73.20 — trading 29.2% below its estimated fair value. The current Accounts Payable is CHF6,584 Mil. Sanofi's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Sanofi (XSWX:SAN), the current Accounts Payable is CHF6,584 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sanofi (XSWX:SAN) Overvalued in 2026?

Based on GuruFocus' analysis, Sanofi stock appears to be undervalued. The current stock price of CHF73.20 is trading 29.2% below its estimated GF Value™ of CHF103.32.

Key valuation signals for XSWX:SAN:

  • Accounts Payable: CHF6,584 Mil
  • GF Value™: CHF103.32 vs. price of CHF73.20 (29.2% below fair value)
  • GF Score™: 91/100 with 2 warning signs

No single metric tells the full story. See the XSWX:SAN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sanofi Business Description

Address 46, Avenue de la Great Army, Paris, FRA, 75017
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
91GF Score

Get the complete analysis for XSWX:SAN

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF73.20
Price
CHF103.32
GF Value